To the Editor:
We recently became aware of apparently wide within-person, day-today fluctuations in total urine protein concentrations measured by the pyrogallol red-molybdate method on the Dade Behring Dimension RxL in some individual patients. In several such patients with suddenly and unexpectedly high proteinuria, electrophoresis of the urine failed to confirm the presence of protein. A retrospective review of 862 total urine protein requests indicated that most patients prescribed aminoglycosides at the time of urine collection had a total urine protein Ͼ150 mg/L. Aminoglycosides are recognized as having significant nephrotoxicity (1 ) . Importantly however, some patients showed sufficient variability in results while still receiving aminoglycosides to raise the question of aminoglycoside interference.
We added six to nine concentrations of gentamicin and tobramycin (both from Pharmacia & Upjohn) individually in the interval 0. At a protein concentration of 100 mg/L, the Dade Behring pyrogallol red-molybdate method showed an overestimate in concentration of Ͼ10% at aminoglycoside concentrations of 6.3-12.5 mg/L. Above these aminoglycoside concentrations there was a progressive increase with each aminoglycoside. The effect was similar for both urine and for the albumin solutions. Changes of 10% did not occur with the 2000 mg/L sample until the aminoglycoside concentration was Ͼ80 mg/L. The influence of the aminoglycosides on both urine and the human albumin solution was statistically significant (ANOVA, P Ͻ0.0001 for both). On the basis of a linear regression model, the aminoglycoside concentrations at which there was a significant increase in measured protein concentration in a urine containing 110 mg/L protein were 4.8 mg/L [confidence interval (CI), 1.2-9.0 mg/L] for gentamicin and 4.1 mg/L (CI, 3.6 -12.7 mg/L) for tobramycin. In a solution containing 110 mg/L human albumin, the concentrations were 5.0 mg/L (CI, 2.0 -10.1 mg/L) and 4.3 mg/L (CI, 3.23-5.33 mg/L), respectively. The Roche and Orsonneau total urine protein methods showed no changes in concentration with the addition of aminoglycosides.
To confirm the clinical relevance of the in vitro observations, we collected three urine samples over a 24-h period from each of three cystic fibrosis patients (patients A, B, and C) receiving tobramycin once per day. These samples were analyzed on the Dade Behring Dimension RxL for urinary protein with the Dade Behring pyrogallol red-molybdate method and for tobramycin with the Dade Behring PETINIA method ( Fig.  1 ).
High concentrations of urinary tobramycin were seen over a 24-h dosing interval. There was an apparent increase in urinary protein concentration after aminoglycoside dosage. That concentration fell in proportion to the decrease in urinary tobramycin concentration. In the absence of aminoglycoside interference, over equivalent 24-h periods, samples from these patients had urinary protein concentrations in the range of 160 -240 mg/L (shaded area in Fig.  1B) .
Aminoglycosides are excreted almost entirely by glomerular filtration. With plasma half-lives of 2-3 h, aminoglycoside concentrations in the urine may be Ͼ200 mg/L. Up to 25% of patients who receive aminoglycosides for more than a few days will develop mild impairment of renal concentrating ability attributable to accumulation of the drug in the proximal tubules (1 ) . Accurate urinary protein measurement is needed to identify renal damage in these patients. In reviewing the patient data, we saw evidence of concern and confusion about the fluctuating results for urinary protein.
We conclude that aminoglycosides produce positive interference with the Dade Behring pyrogallol redmolybdate method for urinary protein estimation but not with other tested pyrogallol red-molybdate methods. Patients with essentially normal urinary protein concentrations but on aminoglycoside therapy had urinary aminoglycoside concentrations sufficiently high, even at the end of a 24-h dosing interval, to produce artifactually increased urinary protein results. The mechanism of the interference is unknown.
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False Hyperprolactinemia Corrected by the Use of Heterophilic Antibodyblocking Agent
To the Editor: The prolactin immunometric assays (IMAs) that have replaced the old RIAs are used for the diagnosis of hyperprolactinemia and for monitoring the effectiveness of subsequent treatment. Two pitfalls have frequently been reported for prolactin assays: the "hook" effect may yield false-negative results when the prolactin concentration is very high (1 ); and the presence in serum of a high proportion of a biologically inactive but immunologically reactive form of prolactin (macroprolactin) may yield false-positive results (2 ) . Another source of false-positive prolactin measurements, i.e., interference from heterophilic antibodies, which was relatively frequent with RIAs (3) (4) (5) , to our knowledge has been reported only once with IMAs (6 ). We describe here a case of antibody interference with a prolactin IMA, which led to unnecessary radiologic investigations and treatment.
In April 1999, a 45-year-old woman under contraceptive treatment (minipill) consulted her physician because of the onset of amenorrhea without galactorrhea. The physical examination was normal except for a small euthyroid goiter (normal thyrotropin). The serum prolactin concentration, determined with the automated VIDAS enzyme IMA (bioMérieux, Marcy-l'Etoile, France), which uses two mouse monoclonal antibodies, was increased [78 g/L at the time of the examination (3rd International Standard 84/500 used as the standard) and 121 g/L several days later]. Pituitary imaging by computed tomography revealed no evidence of prolactinoma. Nevertheless, despite the return of regular menstrual cycles after the pill was stopped, the woman was given antiprolactin treatment with a dopamine receptor agonist drug, Dostinex ® .
In January 2000, the VIDAS prolactin value was still increased (111 g/ L). In February 2000, the patient, who complained of irregular menstrual periods, was referred to our university hospital. Her prolactin concentration, assayed with the Elecsys ® electrochemiluminescent IMA from Roche Diagnostics, which uses two mouse monoclonal antibodies, was markedly decreased (Ͻ0.4 g/L; 3rd International Standard 84/500 used as the standard). The antiprolactin therapy was stopped. In June 2000, the patient again had regular periods and a prolactin concentration (21.6 g/L) within the reference interval, as measured by the Elecsys. The discrepancy between the results obtained by the assays of two manufacturers supported the interference hypothesis. In June 2001, the presence in our laboratory of a VIDAS system prompted us to undertake further investigations on the June 2000 serum sample (stored frozen at Ϫ20°C) to characterize the interference with the VIDAS assay.
The VIDAS prolactin result was Ͼ200 g/L. The results obtained with the Vitros ECi assay (19.1 g/L) from Ortho-Clinical Diagnostics, which uses a sheep polyclonal antibody and a mouse monoclonal antibody, and with the AxSYM assay (18.4 g/L) from Abbott Laboratories, which uses a rabbit polyclonal antibody and a mouse monoclonal antibody, were in agreement with those of the Elecsys assay.
A false-positive result as a consequence of macroprolactinemia was ruled out by the normal recovery (76%) of Elecsys prolactin after the serum was treated with 25% polyethylene glycol (7 ). The hypothesis that an interfering antibody was present was supported by evidence of nonparallel behavior between the suspected sample and the assay calibrators. The 5-to 320-fold dilutions of the serum with the VIDAS prolactin diluent showed increasing recoveries (117-191%), whereas the 2-to 32-fold dilutions of a "normal" serum yielded recoveries of 83-97% (8 ). The addition of mouse, bovine, or rabbit serum (10% and 50%) to the patient's serum was ineffective in decreasing the VIDAS prolactin result. Anti-isotypic human anti-mouse antibodies (HAMAs) were checked with the HAMA-ELISA assay from Medac, which uses mouse IgG immobilized on a plastic surface as the capture antigen and a mouse IgG-horseradish peroxidase conjugate to detect captured HAMAs (positivity threshold reported by the manufacturer, 40 g/L). The result obtained with the patient's serum was weakly positive
